TY - JOUR
T1 - The salubrious effect of tamaxifen on serum marker enzymes, glycoproteins, and lysosomal enzymes level in breast cancer women
AU - Thangaraju, M.
AU - Rameshbabu, J.
AU - Vasavi, H.
AU - Ilanchezhian, S.
AU - Vinitha, R.
AU - Sachdanandam, P.
N1 - Funding Information:
All authors acknowledge with gratitude, the financial support from the Council of Scientific and Industrial Research (Award No. 9/115 [2551/92 EMR-1), New Delhi, India. We thank whole-heartedly the following for their association, co-operation, and philanthropic help: Dr. B. Nagarajan, PhD, Cancer Institute, Madras, Dr. S. Subramanium, MD, and Dr. K. Vijayasarathy, MD, Department of Medical Oncology, Madras Medical College, Madras, India.
PY - 1998
Y1 - 1998
N2 - Tumour markers correlate strongly with prognosis based on tumour burden and surgical resectability. If chemotherapy is extremely effective in certain stage of the disease, the sensitive marker may be of great use in monitoring disease response and drug treatment. Hence, this study was launched to evaluate the changes in tumour marker enzymes like lactate dehydrogenase (LDH), glumate oxaloacetate transaminase (SGOT), glutamate pyruvate transaminase (SGPT), alkaline phosphatase, and acid phosphatase in before and after 3 and 6 months tamoxifen treated breast cancer patients. In addition, the changes in serum glycoproteins viz., hexose, hexosamine, and sialic acid and lysosomal enzymes such as N-acetyl-beta-D-glucosaminidase, beta-D-galactosidase, and beta-D-glucuronidase were analysed in these patients. These values were compared with their age matched healthy control subjects. At 6 months evaluation, the tamoxifen treated postmenopausal breast cancer women showed a statistically significant decreased (p < 0.001, 0.05 respectively) levels of LDH, SGOT, SGPT, alkaline and acid phosphatases than their baseline values. Similarly, the levels of hexose, hexosamine, and sialic acid and N-acetyl-beta-D-glucosaminidase, beta-D-galactosidase, and beta-D-glucuronidase were decreased significantly (p < 0.001)in tamoxifen received postmenopausal women. The result of this study suggested that tamoxifen potentially retard the metastasis of breast cancer as well as the bone demineralisation in postmenopausal breast cancer women. Thus, tamoxifen may also have its antitumour activity through its beneficial effects on tumour marker enzymes and serum proteins in breast cancer women.
AB - Tumour markers correlate strongly with prognosis based on tumour burden and surgical resectability. If chemotherapy is extremely effective in certain stage of the disease, the sensitive marker may be of great use in monitoring disease response and drug treatment. Hence, this study was launched to evaluate the changes in tumour marker enzymes like lactate dehydrogenase (LDH), glumate oxaloacetate transaminase (SGOT), glutamate pyruvate transaminase (SGPT), alkaline phosphatase, and acid phosphatase in before and after 3 and 6 months tamoxifen treated breast cancer patients. In addition, the changes in serum glycoproteins viz., hexose, hexosamine, and sialic acid and lysosomal enzymes such as N-acetyl-beta-D-glucosaminidase, beta-D-galactosidase, and beta-D-glucuronidase were analysed in these patients. These values were compared with their age matched healthy control subjects. At 6 months evaluation, the tamoxifen treated postmenopausal breast cancer women showed a statistically significant decreased (p < 0.001, 0.05 respectively) levels of LDH, SGOT, SGPT, alkaline and acid phosphatases than their baseline values. Similarly, the levels of hexose, hexosamine, and sialic acid and N-acetyl-beta-D-glucosaminidase, beta-D-galactosidase, and beta-D-glucuronidase were decreased significantly (p < 0.001)in tamoxifen received postmenopausal women. The result of this study suggested that tamoxifen potentially retard the metastasis of breast cancer as well as the bone demineralisation in postmenopausal breast cancer women. Thus, tamoxifen may also have its antitumour activity through its beneficial effects on tumour marker enzymes and serum proteins in breast cancer women.
KW - Breast cancer
KW - Glycoproteins
KW - Lysosomal enzymes
KW - Marker enzymes
KW - Tamoxifen
UR - http://www.scopus.com/inward/record.url?scp=0032130329&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032130329&partnerID=8YFLogxK
U2 - 10.1023/A:1006874005764
DO - 10.1023/A:1006874005764
M3 - Article
C2 - 9746215
AN - SCOPUS:0032130329
SN - 0300-8177
VL - 185
SP - 85
EP - 94
JO - Molecular and Cellular Biochemistry
JF - Molecular and Cellular Biochemistry
IS - 1-2
ER -